trending Market Intelligence /marketintelligence/en/news-insights/trending/KSwLOvbzylmV4e1NXhH6AA2 content esgSubNav
In This List

J&J to pay $117M in multistate settlement of surgical mesh litigation

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


J&J to pay $117M in multistate settlement of surgical mesh litigation

Johnson & Johnson will pay close to $117 million in a multistate settlement of litigation over the pharma giant's alleged deceptive marketing practices of its pelvic mesh devices, according to U.S. attorneys general.

The surgical mesh is implanted to support women's pelvic organs.

The settlement, which totals $116.9 million, covers 41 participating states, including Ohio, Delaware, New York and others, as well as Washington, D.C., Delaware Attorney General Kathleen Jennings said in an Oct. 17 statement. Delaware will receive $1.4 million under the settlement.

Meanwhile, Ohio will receive $6.3 million, according to an Oct. 17 announcement by Ohio Attorney General Dave Yost.

The transvaginal surgical mesh devices, manufactured by J&J's Ethicon unit, were alleged to have caused severe pain, urinary problems and other injuries. According to the multistate investigation, J&J misrepresented the devices' safety and did not sufficiently disclose possible side effects.

As part of the settlement, the New Brunswick, N.J.-based pharmaceutical giant is also required to provide full disclosure of risks associated with the devices' risk and provide accurate information on promotional materials and packaging.

J&J was previously ordered by a Philadelphia court to pay $80 million to a woman with injuries from the surgical mesh implants.